Majedie Asset Management Ltd Sells 8,129 Shares of Celgene Co. (CELG)

Majedie Asset Management Ltd lowered its holdings in shares of Celgene Co. (NASDAQ:CELG) by 12.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,191 shares of the biopharmaceutical company’s stock after selling 8,129 shares during the quarter. Majedie Asset Management Ltd’s holdings in Celgene were worth $4,939,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Ayalon Holdings Ltd. acquired a new stake in Celgene in the 2nd quarter worth $100,000. Atlantic Trust LLC acquired a new stake in shares of Celgene during the 2nd quarter valued at about $101,000. Acropolis Investment Management LLC acquired a new stake in shares of Celgene during the 2nd quarter valued at about $112,000. Moneta Group Investment Advisors LLC boosted its position in shares of Celgene by 2,688.6% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 9,921 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Celgene during the 3rd quarter valued at about $132,000. Institutional investors and hedge funds own 72.98% of the company’s stock.

CELG has been the topic of several recent research reports. BidaskClub lowered shares of Celgene from a “hold” rating to a “sell” rating in a research report on Wednesday, October 24th. Zacks Investment Research lowered shares of Celgene from a “buy” rating to a “hold” rating in a research report on Wednesday, September 26th. Mizuho set a $117.00 target price on shares of Celgene and gave the company a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a research report on Thursday, October 25th. Finally, Cantor Fitzgerald initiated coverage on shares of Celgene in a research report on Monday, October 1st. They set an “overweight” rating and a $100.00 target price on the stock. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $117.91.

In other news, Director Ernest Mario sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $92.32, for a total value of $1,107,840.00. Following the completion of the transaction, the director now owns 44,413 shares in the company, valued at $4,100,208.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John H. Weiland purchased 5,575 shares of Celgene stock in a transaction dated Tuesday, August 7th. The stock was bought at an average price of $89.73 per share, with a total value of $500,244.75. The disclosure for this purchase can be found here. 0.39% of the stock is currently owned by corporate insiders.

Shares of NASDAQ:CELG opened at $74.19 on Friday. Celgene Co. has a 52 week low of $70.09 and a 52 week high of $110.81. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 4.06. The company has a market capitalization of $50.07 billion, a price-to-earnings ratio of 10.85, a PEG ratio of 0.44 and a beta of 1.53.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.02 by $0.27. Celgene had a net margin of 19.64% and a return on equity of 108.76%. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.83 billion. On average, research analysts anticipate that Celgene Co. will post 7.45 EPS for the current year.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply